The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer (leptin)
|ClinicalTrials.gov Identifier: NCT01643148|
Recruitment Status : Completed
First Posted : July 18, 2012
Last Update Posted : July 18, 2012
Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.
Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.
Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay.
Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.
|Condition or disease|
|Female Breast Carcinoma|
|Study Type :||Observational|
|Actual Enrollment :||88 participants|
|Observational Model:||Case Control|
|Official Title:||Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||July 2012|
breast cancer patients (cases)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01643148
|Principal Investigator:||Jonnathan Guadalupe Santillán Benítez, MSc||Autonomus University Of the State Of México|
|Study Director:||Leobardo Manuel Gómez Oliván, PhD||Universidad Autonoma del Estado de Mexico|
|Study Chair:||Hugo Mendieta Zeron, PhD||Autonomous University of the State of Mexico|